A Phase II trial of 8 weeks of degarelix for prostate volume reduction: Efficacy and hormonal recovery.
暂无分享,去创建一个
J. Crook | R. Halperin | A. Tétreault-Laflamme | D. Bowes | F. Bachand | M. Gaztañaga | C. Araujo | J. Rose | L. Pilote | A. Ots | D. Petrik | M. Korzeniowski | J. Jazwal | D. Kim
[1] W. J. Morris,et al. Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cance , 2017, International journal of radiation oncology, biology, physics.
[2] Sang Eun Lee,et al. Efficacy and safety of degarelix in Korean patients with prostate cancer requiring androgen deprivation therapy: Open-label multicenter phase III study , 2015, Prostate international.
[3] W. Wallace,et al. A Validated Age-Related Normative Model for Male Total Testosterone Shows Increasing Variance but No Decline after Age 40 Years , 2014, PloS one.
[4] V. Khoo,et al. Neoadjuvant androgen deprivation therapy for prostate volume reduction, lower urinary tract symptom relief and quality of life improvement in men with intermediate- to high-risk prostate cancer: a randomised non-inferiority trial of degarelix versus goserelin plus bicalutamide. , 2013, Clinical oncology (Royal College of Radiologists (Great Britain)).
[5] L. Tankó,et al. Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide , 2012, BJU international.
[6] P. Hoskin,et al. Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[7] Jette Borg,et al. 10-year experience with I-125 prostate brachytherapy at the Princess Margaret Hospital: results for 1,100 patients. , 2011, International journal of radiation oncology, biology, physics.
[8] F. Vicini,et al. Dose escalation improves cancer-related events at 10 years for intermediate- and high-risk prostate cancer patients treated with hypofractionated high-dose-rate boost and external beam radiotherapy. , 2011, International journal of radiation oncology, biology, physics.
[9] K. Wallner,et al. Long-term outcome for clinically localized prostate cancer treated with permanent interstitial brachytherapy. , 2010, International journal of radiation oncology, biology, physics.
[10] P. Saylor,et al. Metabolic complications of androgen deprivation therapy for prostate cancer. , 2009, The Journal of urology.
[11] Howard Pai,et al. Predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: long-term outcome in 712 consecutive patients. , 2009, International journal of radiation oncology, biology, physics.
[12] G. Lockwood,et al. Final report of multicenter Canadian Phase III randomized trial of 3 versus 8 months of neoadjuvant androgen deprivation therapy before conventional-dose radiotherapy for clinically localized prostate cancer. , 2009, International journal of radiation oncology, biology, physics.
[13] F. Schröder,et al. The efficacy and safety of degarelix: a 12‐month, comparative, randomized, open‐label, parallel‐group phase III study in patients with prostate cancer , 2008, BJU international.
[14] N. Mabjeesh,et al. Preimplant predictive factors of urinary retention after iodine 125 prostate brachytherapy. , 2007, Urology.
[15] R. Stock,et al. The effect of brachytherapy, external beam irradiation and hormonal therapy on prostate volume. , 2007, The Journal of urology.
[16] K. Wallner,et al. Efficacy of neoadjuvant bicalutamide and dutasteride as a cytoreductive regimen before prostate brachytherapy. , 2006, Urology.
[17] D. Dearnaley,et al. Recovery of serum testosterone after neoadjuvant androgen deprivation therapy and radical radiotherapy in localized prostate cancer , 2006, BJU international.
[18] Louis Potters,et al. 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. , 2005, The Journal of urology.
[19] L. Schour,et al. High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results. , 2005, International journal of radiation oncology, biology, physics.
[20] B. Davis,et al. Prostate Volume Before and After Permanent Prostate Brachytherapy in Patients Receiving Neoadjuvant Androgen Suppression , 2004, Cancer journal.
[21] K. Wallner,et al. Androgen deprivation-induced changes in prostate anatomy predict urinary morbidity after permanent interstitial brachytherapy. , 2004, International journal of radiation oncology, biology, physics.
[22] A. Henderson,et al. Is bicalutamide equivalent to goserelin for prostate volume reduction before radiation therapy? A prospective, observational study. , 2003, Clinical oncology (Royal College of Radiologists (Great Britain)).
[23] K. Yoshimura,et al. Neoadjuvant flutamide monotherapy for locally confined prostate cancer , 2003, International journal of urology : official journal of the Japanese Urological Association.
[24] F. Vicini,et al. Prostate volume reduction with androgen deprivation therapy before interstitial brachytherapy. , 2002, The Journal of urology.
[25] H M Sandler,et al. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. , 2000, Urology.
[26] P. Arger,et al. The effect of androgen deprivation on the early changes in prostate volume following transperineal ultrasound guided interstitial therapy for localized carcinoma of the prostate. , 1999, International journal of radiation oncology, biology, physics.
[27] W Cavanagh,et al. Use of TRUS to predict pubic arch interference of prostate brachytherapy. , 1999, International journal of radiation oncology, biology, physics.
[28] É. Vigneault,et al. Randomized non-inferiority trial of Bicalutamide and Dutasteride versus LHRH agonists for prostate volume reduction prior to I-125 permanent implant brachytherapy for prostate cancer. , 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[29] D. Grobbee,et al. Endogenous sex hormones and metabolic syndrome in aging men. , 2005, The Journal of clinical endocrinology and metabolism.
[30] L. Potters,et al. Urinary morbidity following ultrasound-guided transperineal prostate seed implantation. , 1999, International journal of radiation oncology, biology, physics.